France IVD Market by Product Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and by End Users (Standalone Laboratory, Hospitals, Academic and Medical Schools, Point of Care Testing, and Others) - Opportunity Analysis and Industry Forecast, 2017-2023

August 2017 | 140 pages | ID: FEA63AE1E9FEN
Allied Market Research

Abstracts

In vitro diagnostics (IVD) refers to the technique wherein the biological samples such as stool, tissues, blood, urine, and other body fluids are examined with the help of various medical devices and reagents. These body fluids are generally taken from the human body to detect infections and diseases. IVD tests are generally performed in hospital based laboratories, stand-alone laboratories, and point-of-care centres for the examination of diseases conditions. Various technologies used for test sample preparation include microarray techniques, polymerase chain reaction, mass spectrometry, and sequencing technologies. The France IVD market accounted for $2,943 million in 2016, and is estimated to reach $4,509 million by 2023, growing at a CAGR of 6.2% during the analysis period of (2017–2023) IVD market.

The market is segmented on the basis of product type, techniques, application, and end user. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of technique, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user it is classified into hospitals, academic and medical schools, point of care testing, and others.

KEY BENEFITS FOR STAKEHOLDERS

• Comprehensive analysis of factors that drive and restrict the growth of the France IVD market is provided.
• The projections in the market are made by studying the current and future market trends for the period (2016–2023) in terms of value.
• Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
• Key market players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

• Reagents
• Instruments
• Software and Services

By Techniques

• Immunodiagnostics
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chemiluminescence Immunoassays (CLIAS)
• Fluorescence Immunoassays (FIAS)
• Colorimetric Immunoassays (CIS)
• Rapid Tests
• Enzyme-Linked Immunospot Assays (ELISPOT)
• Radioimmunoassay
• Western Blot
• Blood Testing
• Molecular Diagnostics
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Hybridization
• DNA Diagnostics
• Microarrays
• Others
• Tissue Diagnostics
• Clinical Chemistry
• Basic Metabolic Panel
• Liver Panel
• Lipid Profile
• Thyroid Function Panel
• Renal Profile
• Electrolyte Panel
• Specialty Chemicals
• Other IVD Techniques

By Application

• Infectious Diseases
• Cancer
• Cardiac Diseases
• Immune System Disorders
• Nephrological Diseases
• Gastrointestinal Diseases
• Other Indications

By End Users

• Standalone Laboratory
• Hospitals
• Academic and Medical Schools
• Point of Care Testing
• Others
• Others

List of players profiled in the report

• Thermo Fisher Scientific Inc.
• Alere Inc.
• Biomerieux
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Becton Dickinson and Company
• Bio-Rad Laboratories
• Bayer AG
• Sysmex Corporation
• Johnson & Johnson

Contents

CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
  1.4.1 Secondary research
  1.4.2 Primary research
  1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
  3.2.1 Top investment pockets
  3.2.2 Top winning strategies
3.3 PORTERS FIVE FORCES ANALYSIS
  3.3.1 Bargaining power of suppliers
  3.3.2 Bargaining power of buyers
  3.3.3 Threat of new entrants
  3.3.4 Threat of substitute
  3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
  3.5.1 Drivers
    3.5.1.1 Increasing incidence of chronic and infectious diseases
    3.5.1.2 Technological advancements in IVD
    3.5.1.3 Emergence of minimal invasive technologies
    3.5.1.4 Increasing government expenditures on healthcare
    3.5.1.5 Increase in popularity of personalized medicine approach
  3.5.2 Restraint
    3.5.2.1 Unclear reimbursement policies
    3.5.2.2 Stringent regulatory policies
  3.5.3 Opportunity
    3.5.3.1 Potential opportunities for outsourcing
    3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

4.1 OVERVIEW
  4.1.1 Market size and forecast
4.2 REAGENTS
  4.2.1 Key market trends
  4.2.2 Key growth factors and opportunities
  4.2.3 Market size and forecast
4.3 INSTRUMENTS
  4.3.1 Key market trends
  4.3.2 Key growth factors and opportunities
  4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
  4.4.1 Key market trends
  4.4.2 Key growth factors and opportunities
  4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

5.1 OVERVIEW
  5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
  5.2.1 Key market trends
  5.2.2 Key growth factors and opportunities
  5.2.3 Market size and forecast
  5.2.4 Enzyme-linked immunosorbent assay (ELISA)
    5.2.4.1 Market size and forecast
    5.2.4.2 Chemiluminescence immunoassay (CLIA)
      5.2.4.2.1 Market size and forecast
    5.2.4.3 Fluorescence immunoassay (FIA)
      5.2.4.3.1 Market size and forecast
    5.2.4.4 Colorimetric immunoassay (CI)
      5.2.4.4.1 Market size and forecast
  5.2.5 Rapid tests
    5.2.5.1 Market size and forecast
  5.2.6 Enzyme-linked immunospot (ELISPOT)
    5.2.6.1 Market size and forecast
  5.2.7 Radioimmunoassay (RIA)
    5.2.7.1 Market size and forecast
  5.2.8 Western blot
    5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
  5.3.1 Key market trends
  5.3.2 Key growth factors and opportunities
  5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
  5.4.1 Key market trends
  5.4.2 Key growth factors and opportunities
  5.4.3 Market size and forecast
  5.4.4 Polymerize chain reaction (PCR)
    5.4.4.1 Market size and forecast
  5.4.5 Isothermal nucleic acid technology (INAAT)
    5.4.5.1 Market size and forecast
  5.4.6 Hybridization
    5.4.6.1 Market size and forecast
  5.4.7 DNA diagnostics
    5.4.7.1 Market size and forecast
  5.4.8 Microarray
    5.4.8.1 Market size and forecast
  5.4.9 Others
    5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
  5.5.1 Key market trends
  5.5.2 Key growth factors and opportunities
  5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
  5.6.1 Key market trends
  5.6.2 Key growth factors and opportunities
  5.6.3 Market size and forecast
  5.6.4 Basic metabolic panel
    5.6.4.1 Market size and forecast
  5.6.5 Liver panel
    5.6.5.1 Market size and forecast
  5.6.6 Renal profile
    5.6.6.1 Market size and forecast
  5.6.7 Lipid profile
    5.6.7.1 Market size and forecast
  5.6.8 Thyroid function panel
    5.6.8.1 Market size and forecast
  5.6.9 Electrolyte panel
    5.6.9.1 Market size and forecast
  5.6.10 Speciality chemicals
    5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
  5.7.1 Key market trends
  5.7.2 Key growth factors and opportunities
  5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

6.1 INFECTIOUS DISEASES
  6.1.1 Key market trends
  6.1.2 Key growth factors and opportunities
  6.1.3 Market size and forecast
6.2 CANCER
  6.2.1 Key market trends
  6.2.2 Key growth factors and opportunities
  6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
  6.3.1 Key market trends
  6.3.2 Key growth factors and opportunities
  6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
  6.4.1 Key market trends
  6.4.2 Key growth factors and opportunities
  6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
  6.5.1 Key market trends
  6.5.2 Key growth factors and opportunities
  6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
  6.6.1 Key market trends
  6.6.2 Key growth factors and opportunities
  6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
  6.7.1 Key market trends
  6.7.2 Key growth factors and opportunities
  6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

7.1 STANDALONE LABORATORIES
  7.1.1 Market size and forecast
7.2 HOSPITALS
  7.2.1 Key market trends
  7.2.2 Key growth factors and opportunities
  7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
  7.3.1 Key market trends
  7.3.2 Key growth factors and opportunities
  7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
  7.4.1 Key market trends
  7.4.2 Key growth factors and opportunities
  7.4.3 Market size and forecast
7.5 OTHERS END-USER
  7.5.1 Key market trends
  7.5.2 Key growth factors and opportunities
  7.5.3 Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1 THERMO FISHER SCIENTIFIC INC.
  8.1.1 Company overview
  8.1.2 Business performance
  8.1.3 Key strategies and development
8.2 ALERE INC.
  8.2.1 Company overview
  8.2.2 Business performance
  8.2.3 Key strategies and developments
8.3 BIOMERIEUX
  8.3.1 Company overview
  8.3.2 Business performance
  8.3.3 Key strategies and developments
8.4 DANAHER CORPORATION
  8.4.1 Company overview
  8.4.2 Business performance
  8.4.3 Key strategies and development
8.5 F. HOFFMANN-LA ROCHE AG
  8.5.1 Company overview
  8.5.2 Business performance
  8.5.3 Key strategies and developments
8.6 BECTON DICKINSON AND COMPANY
  8.6.1 Company overview
  8.6.2 Business performance
  8.6.3 Key strategies and development
8.7 BIO-RAD LABORATORIES
  8.7.1 Company overview
  8.7.2 Business performance
  8.7.3 Key strategies and developments
8.8 BAYER AG
  8.8.1 Company overview
  8.8.2 Business performance
  8.8.3 Key strategies and development
8.9 SYSMEX CORPORATION
  8.9.1 Company overview
  8.9.2 Business performance
  8.9.3 Key strategies and developments
8.10 JOHNSON & JOHNSON
  8.10.1 Company overview
  8.10.2 Business performance
  8.10.3 Key strategies and development

List Of Tables

LIST OF TABLES

TABLE 1 INCIDENCE OF DISEASES
TABLE 2 FRANCE IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 FRANCE IVD REAGENTS MARKET, 2016-2023 ($MILLION)
TABLE 4 FRANCE IVD INSTRUMENTS MARKET, 2016-2023 ($MILLION)
TABLE 5 FRANCE IVD SOFTWARE & SERVICES MARKET, 2016-2023 ($MILLION)
TABLE 6 FRANCE IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 FRANCE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 FRANCE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 9 FRANCE IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 FRANCE IVD BLOOD TESTING TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 11 FRANCE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 FRANCE IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 13 FRANCE IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, 2016-2023, ($MILLION)
TABLE 14 FRANCE IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 15 FRANCE OTHER IVD TECHNIQUES MARKET, 2016-2023, ($MILLION)
TABLE 16 FRANCE IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 FRANCE IVD INFECTIOUS DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 18 FRANCE IVD CANCER MARKET, 2016-2023 ($MILLION)
TABLE 19 FRANCE IVD CARDIAC DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 20 FRANCE IVD IMMUNE SYSTEM DISORDER MARKET, 2016-2023 ($MILLION)
TABLE 21 FRANCE IVD NEPHROLOGICAL DISEASES MARKET, 2016-2023, ($MILLION)
TABLE 22 FRANCE IVD GASTROINTESTINAL DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 23 FRANCE IVD OTHER INDICATION MARKET, 2016-2023 ($MILLION)
TABLE 24 FRANCE IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 FRANCE IVD STANDALONE LABORATORIES MARKET, 2016-2023 ($MILLION)
TABLE 26 FRANCE IVD HOSPITALS MARKET, 2016-2023 ($MILLION)
TABLE 27 FRANCE IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, 2016-2023 ($MILLION)
TABLE 28 FRANCE IVD POINT OF CARE MARKET, 2016-2023 ($MILLION)
TABLE 29 FRANCE IVD OTHER END-USER MARKET, 2016-2023 ($MILLION)
TABLE 30 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 31 ALERE INC. COMPANY SNAPSHOT
TABLE 32 BIOMERIEUX COMPANY SNAPSHOT
TABLE 33 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 34 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 35 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 36 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 37 BAYER AG COMPANY SNAPSHOT
TABLE 38 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 39 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTERS FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 FRANCE CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 FRANCE FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 FRANCE COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 FRANCE RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 FRANCE ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 FRANCE RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 FRANCE WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 FRANCE POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 FRANCE ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 FRANCE HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 FRANCE DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 FRANCE MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 FRANCE OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 FRANCE BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 FRANCE LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 FRANCE RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 FRANCE LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 FRANCE THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 FRANCE ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 FRANCE SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)